Feeds:
Posts
Comments

Posts Tagged ‘University of Southern California’

UPDATED on 3/14/2022 – Call for the abandonment of the Off-pump CABG surgery (OPCAB) in the On-pump / Off-pump Debate, +100 Research Studies

Curator: Aviva Lev-Ari, PhD, RN

UPDATED on 3/14/2022

Debate over? On-pump CABG, off-pump CABG lead to similar 10-year outcomes

Surgeons have debated for 20 years over which method is better—traditional on-pump surgery (which uses an extracorporeal membrane oxygenation [ECMO] heart-lung machine to circulate and oxygenate the the blood while the heart is stopped) or off-pump, which eliminates complications potentially caused by ECMO but makes the procedure more technically difficult. Monitoring the post-CABG outcomes of all original ROOBY trial patients, this phase IV clinical trial represents the largest U.S.-based, multi-center, randomized clinical trial comparing off-pump versus on-pump patients.

The researchers tracked more than 1,000 veterans treated with on-pump procedures and more than 1,000 veterans treated with off-pump procedures over 10 years. These veterans are a national cohort from 18 VA Centers. The average age at the time of surgery for both groups was about 63 years old.

Mortality similar for on-pump vs off-pump CABG

According to the authors, no significant 10-year treatment-related differences were documented for any primary or secondary post-CABG endpoint rates. Endpoints included repeat CABG, other heart revascularization procedures, and changes in cardiac symptoms. The death rates at 10 years were 34.2 percent for the off-pump group and 31.1 for the on-pump group.

Although the 10-year outcome rates were not different, the researchers did document a slightly shorter revascularization-free survival period among patients in the off-pump group. Additionally, the median time to death in the off-pump patients was 5.6 years, and the median time to death in the on-pump patients was 6.1 years. Across all study outcomes, moreover, no off-pump advantages were found.

The analyses for cardiac outcomes for these two groups were completed from May 2017 to December 2021.

“While our findings may not settle the ongoing debate about on-pump versus off-pump advantages with CABG, the data is strong to support the notion that for patients who are viable candidates for either procedure, no benefits were found for using an off-pump procedure,” lead author Laurie Shroyer, PhD, professor of surgery in the Renaissance School of Medicine at Stony Brook University and Northport Veteran Affairs (VA) Medical Center WOC Health Science Officer, said in a statement. “As these veterans were nearly all men, the findings should not be generalized to women or non-veterans. Thus, surgeons should choose the best CABG method based each individual patient’s risks and in light of the surgeon’s own technical CABG expertise and post-CABG outcome experiences. In summary, each CABG patient’s care should be customized to meet their unique needs.”

The study authors write that the findings in their report do concur with the 2015 consensus statement by the International Society for Minimally Invasive Cardiothoracic Surgery.[2] That consensus statement says off-pump CABG may be associated with an increased long-term risk of reintervention and death. Yet, the authors found “10-year symptomatic benefit of patients who underwent CABG was not influenced by the treatment approach.”

“These operations were performed at a time when this revascularization approach was considered novel, and it served as an impetus for a few dedicated surgeons to advance it further to become a minimally invasive robotic and often hybrid operation,” Thomas V. Bilfinger, MD, a professor of cardiothoracic surgery at the Renaissance School of Medicine who was not involved in the study, said in the same statement. “While it is good to know there is no difference in the long-term outcomes between off and on pump groups, the lasting importance of this research is that it provides a seed to newer procedural developments that will lead to long-lasting beneficial outcomes for today’s patients.”

References:

1. Quin JA, Wagner TH, Hattler B, et al. Ten-Year Outcomes of Off-Pump vs On-Pump Coronary Artery Bypass Grafting in the Department of Veterans Affairs: A Randomized Clinical Trial. JAMA Surg. Published online February 16, 2022. doi:10.1001/jamasurg.2021.7578.

2. John D. Puskas,Janet Martin, Davy C. H. Cheng, et al. ISMICS Consensus Conference and Statements of Randomized Controlled Trials of Off-Pump versus Conventional Coronary Artery Bypass Surgery. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. First published online July 1, 2015. DOI.org/10.1097/imi.0000000000000184. 

 

Related CABG Content:

Still No. 1: CABG outperforms FFR-PCI when treating CAD

New ACC/AHA guidelines detail updated recommendations for PCI, CABG

CABG still the ‘treatment of choice’ for patients with complex three-vessel CAD

PCI and CABG for left main CAD associated with similar all-cause mortality rates

 

@@@@

The curator shadowed Dr. J. Walker @MGH performing On-pump CABG in 1/2005 and On-pump CABG performed @Texas Heart Institute in 2/2005, and attended demos of ECMO at Vanderbilt Medical Center, Department of Surgery, Perfusion Program, 8/2005

Public release date: 22-Jul-2013

Contact: Gina Orlando
gina.orlando@bmc.org
617-638-8490
Boston University Medical Center

BMC surgeon recommends off-pump coronary artery bypass grafting be abandoned

(Boston) – In a Special Report in the current issue of Circulation, Boston Medical Center cardiothoracic surgeon Harold Lazar, MD, has found that off-pump coronary artery bypass graft (OPCAB) surgery has failed to show any significant improvement in short-term morbidity or mortality as compared to the traditional on-pump coronary artery bypass graft (CABG) surgery. He recommends that the technique be abandoned, unless surgeons who perform off-pump surgery can show that their own results are as good as results reported with the traditional on-pump surgery.

During off-pump coronary artery bypass graft surgery, the heart is still beating while the graft attachments are made to bypass a blockage. While performing on-pump CABG surgery, the heart is stopped and a heart-lung machine takes over the work for the heart and lungs. This method has been an effective, safe and time-proven technique and is considered the gold standard with which all other surgical revascularization methods have been compared. However, performing coronary revascularization this way can result in myocardial ischemic injury, neurocognitive deficits, and strokes and activate inflammatory pathways that contribute to pulmonary, renal and hematologic complications.

In order to accurately compare the advantages and disadvantages of OPCAB and to determine what, if any, role it should have in the practice of surgical coronary artery revascularization, Lazar examined clinical data from numerous studies worldwide and found the OPCAB technique had failed to show any significant improvement in short-term morbidity or mortality.

According to Lazar a major impetus for performing OPCAB was to avoid the possible detrimental effects of cardiopulmonary bypass, which include activation of inflammatory pathways, changes in neurological and cognitive function and alterations in quality of life. “However, patients undergoing OPCAB have not shown any benefits in these areas,” said Lazar, a professor of surgery at Boston University School Medicine. “Even in those studies in which OPCAB has resulted in a small improvement in early postoperative outcomes, these improvements are no longer apparent on long-term follow-up,” he added.

In fact, several studies suggest that long-term survival may be significantly reduced in OPCAB patients compared with patients in whom on-pump techniques were used. Lazar explains that this may be attributable to the significant increase in incomplete revascularization seen in OPCAB patients and may be responsible for the increase in recurrent angina and need for revascularization procedures seen in OPCAB patients.

“Unless individual surgeons can demonstrate that they can achieve short- and long-term outcomes with OPCABG that are comparable to on-pump CABG results, they should abandon this technique,” said Lazar.

 

The debate over abandoning off-pump CABG surgery

JULY 29, 2013 

Boston, MA Off-pump coronary artery bypass graft (OPCAB) surgery is not as durable or as effective as coronary surgery performed with cardiopulmonary bypass (CPB) and should be abandoned in favor of conventional CABG surgery, according to one expert.

In the July 23, 2013 issue of CirculationDr Harold Lazar (Boston Medical Center, MA) argues that the primary focus of surgical coronary revascularization is complete revascularization and a technically perfect anastomosis that uses the best conduits with a minimal amount of hemodynamic instability. He adds that the procedure should be able to be performed “under all circumstances, on all patients, at all institutions, regardless of their cardiac volume.

“We must not forget that patients are sent for surgical revascularization because medical management has failed, their cardiologists believe that stents will not result in complete revascularization, and the goal is for optimal long-term survival and enhanced freedom from recurrent angina and the need for [repeat] revascularization,” writes Lazar. “These goals can be best achieved with on-pump CABG surgery.”

Dr Robbin Cohen (University of Southern California, LA), on the other hand, said that many physicians are routine off-pump CABG surgeons and the data suggest that results achieved by experienced operators are excellent. It is also a cheaper operation in experienced hands. He does not believe that OPCAB should be abandoned but acknowledged there is a need to better identify the ideal patient who would benefit from the procedure.

While there is yet no consensus and no studies have identified subgroups with better results, the ideal OPCAB candidate is one with a severely diseased descending aorta and those with single-vessel or two-vessel disease—in other words, a patient with favorable anatomy that doesn’t require moving the heart around too much, he said.

“I don’t doubt that I have treated some patients with off-pump surgery where if I had put them on the pump I would have killed them,” Cohen told heartwire.

Looking at the big picture

In his perspective, Lazar analyzes previously published retrospective studies and prospective, randomized controlled clinical trials, including the Randomized On/Off Bypass (ROOBY), Smart Management of Arterial Revascularization Therapy (SMART), and Coronary Artery Bypass Surgery Off- or On-Pump Revascularization (CORONARY) studies.

In ROOBY, the primary short-term end point of death and major cardiovascular events at 30 days was similar in the on-pump and off-pump treatment arms, while cardiac-related mortality and major adverse events were higher in the OPCAB arm at one year. The SMART trial also failed to show a mortality benefit with OPCAB. The CORONARY investigators reported no difference in the composite of death, nonfatal cerebrovascular accidents, nonfatal MIs, or new renal failure requiring dialysis between OPCAB and on-pump CABG surgery. In CORONARY, there was also no difference in quality-of-life scores and neurocognitive function at one year.

Importantly, Lazar says the data from published meta-analyses show that OPCAB patients tend to receive fewer grafts and have a higher incidence of incomplete revascularization. “Despite advances in stabilizers and other equipment, it may be difficult to graft inferior and posterolateral vessels because of right and left ventricular distension and hemodynamic changes,” he writes.

Abandoned? Not so fast, says another expert

So, will OPCAB be abandoned? Not likely, says Cohen. OPCAB is performed often in other countries, mainly because the procedure is quicker and has lower costs than conventional CABG surgery. Cohen had high praise for the systematic review by Lazar, however, noting that the OPCAB vs on-pump CABG debate is a complicated topic and nearly each month brings a new review, journal article, or other analysis in the medical journals.

“Early on, most of us assumed that the morbidity associated with cardiac surgery, that being stroke, renal failure, and so on, was the result of cardiopulmonary bypass,” said Cohen. “And when we started doing off-pump procedures, we assumed that the morbidity would be eliminated. That wasn’t the case. Some of the early studies showed an advantage with blood use and sometimes with the utilization of resources, but morbidity and mortality with the two surgeries were the same.”

Cohen addressed the criticism that OPCAB provides incomplete revascularization compared with on-pump CABG and that the anastomoses are not as good, saying these are all valid criticisms of the procedure. He agreed with Lazar’s point that if surgeons must cross over from OPCAB to conventional bypass, the outcomes are poor. To date, however, OPCAB “has been a moving target,” he added, noting that there has been a move toward addressing these shortcomings.

At one point, Cohen said his group was performing up to 90% of cardiac surgeries with OPCAB but now do just 10% of procedures off-pump. The reasons for decline in use include all of the previously cited reasons:

  • incomplete revascularization,
  • poorer anastomoses, and
  • no reduction in morbidity and mortality to show it is better than conventional CABG, as well the fact that
  • it is difficult to teach to residents.

For OPCAB to move forward, he said that research needs to provide evidence that the procedure is as least as effective and as durable as on-pump CABG. There is also a need to identify specific patient subgroups that would benefit from OPCAB, such as

  • older patients, those with
  • existing renal failure, or
  • patients who have previously had a stroke.

Source

  1. Lazar HL. Should off-pump coronary artery bypass grafting be abandoned? Circulation 2013; 128:406-413. 

 

Related links

Lazar and Cohen report no conflicts of interest. 

http://www.theheart.org/article/1564393.do?utm_medium=email&utm_source=20130731_heartwire&utm_campaign=newsletter

REVIEWS in

http://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed_reviews&from_uid=23877063

Should off-pump coronary artery bypass grafting be abandoned?

Lazar HL.

Circulation. 2013 Jul 23;128(4):406-13. doi: 10.1161/CIRCULATIONAHA.113.003388. No abstract available.

PMID: 23877063 [PubMed – in process]

Related citations

Off-pump coronary artery bypass grafting: simple concept but potentially sublime scientific value.

Ngaage DL.

Med Sci Monit. 2004 Mar;10(3):RA47-54. Epub 2004 Mar 1. Review.

PMID: 14976442 [PubMed – indexed for MEDLINE]

Related citations

Coronary artery surgery: conventional coronary artery bypass grafting versus off-pump coronary artery bypass grafting.

Salzberg SP, Adams DH, Filsoufi F.

Curr Opin Cardiol. 2005 Nov;20(6):509-16. Review.

PMID: 16234622 [PubMed – indexed for MEDLINE]

Related citations

Outcomes of off-pump coronary artery bypass surgery: current best available evidence.

Raja SG, Berg GA.

Indian Heart J. 2007 Jan-Feb;59(1):15-27. Review.

PMID: 19098331 [PubMed – indexed for MEDLINE]

Related citations

Off-pump coronary artery bypass grafting through sternotomy: for whom?

Noora J, Puskas JD.

Curr Opin Cardiol. 2006 Nov;21(6):573-7. Review.

PMID: 17053406 [PubMed – indexed for MEDLINE]

Related citations

Reoperative off-pump coronary artery bypass grafting: current outcomes, concerns and controversies.

Raja SG, Amrani M.

Expert Rev Cardiovasc Ther. 2010 May;8(5):685-94. doi: 10.1586/erc.10.14. Review.

PMID: 20450302 [PubMed – indexed for MEDLINE]

Related citations

Off-pump versus on-pump coronary artery bypass grafting.

Halkos ME, Puskas JD.

Surg Clin North Am. 2009 Aug;89(4):913-22, ix. doi: 10.1016/j.suc.2009.06.015. Review.

PMID: 19782844 [PubMed – indexed for MEDLINE]

 

Select item 228458138.

Myocardial revascularization for the elderly: current options, role of off-pump coronary artery bypass grafting and outcomes.

Raja SG.

Curr Cardiol Rev. 2012 Feb;8(1):26-36. Review.

PMID: 22845813 [PubMed – indexed for MEDLINE]  Free PMC Article

Related citations

Current status of off-pump coronary artery bypass surgery.

Raja SG, Dreyfus GD.

Asian Cardiovasc Thorac Ann. 2008 Apr;16(2):164-78. Review.

PMID: 18381881 [PubMed – indexed for MEDLINE]

Related citations

Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease.

Møller CH, Penninga L, Wetterslev J, Steinbrüchel DA, Gluud C.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD007224. doi: 10.1002/14651858.CD007224.pub2. Review.

PMID: 22419321 [PubMed – indexed for MEDLINE]

Related citations

REFERENCES in 

http://www.ncbi.nlm.nih.gov/pubmed

1.

Should off-pump coronary artery bypass grafting be abandoned?

Lazar HL.

Circulation. 2013 Jul 23;128(4):406-13. doi: 10.1161/CIRCULATIONAHA.113.003388. No abstract available.

PMID: 23877063 [PubMed – in process]

Related citations

Select item 14762348

 

2.

Propensity case-matched analysis of off-pump coronary artery bypass grafting in patients with atheromatous aortic disease.

Sharony R, Grossi EA, Saunders PC, Galloway AC, Applebaum R, Ribakove GH, Culliford AT, Kanchuger M, Kronzon I, Colvin SB.

J Thorac Cardiovasc Surg. 2004 Feb;127(2):406-13.

PMID: 14762348 [PubMed – indexed for MEDLINE]

Related citations

Select item 14752427

 

3.

Comparison of coronary bypass surgery with and without cardiopulmonary bypass in patients with multivessel disease.

Mack MJ, Pfister A, Bachand D, Emery R, Magee MJ, Connolly M, Subramanian V.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):167-73.

PMID: 14752427 [PubMed – indexed for MEDLINE]

Related citations

Select item 12324731

 

4.

Intrapulmonary shunt after cardiopulmonary bypass: the use of vital capacity maneuvers versus off-pump coronary artery bypass grafting.

Tschernko EM, Bambazek A, Wisser W, Partik B, Jantsch U, Kubin K, Ehrlich M, Klimscha W, Grimm M, Keznickl FP.

J Thorac Cardiovasc Surg. 2002 Oct;124(4):732-8.

PMID: 12324731 [PubMed – indexed for MEDLINE]

Related citations

Select item 14976442

 

5.

Off-pump coronary artery bypass grafting: simple concept but potentially sublime scientific value.

Ngaage DL.

Med Sci Monit. 2004 Mar;10(3):RA47-54. Epub 2004 Mar 1. Review.

PMID: 14976442 [PubMed – indexed for MEDLINE]

Related citations

Select item 18455592

 

6.

Myocardial injury in coronary artery bypass grafting: on-pump versus off-pump comparison by measuring high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty acid-binding protein, creatine kinase-MB, and myoglobin release.

Chowdhury UK, Malik V, Yadav R, Seth S, Ramakrishnan L, Kalaivani M, Reddy SM, Subramaniam GK, Govindappa R, Kakani M.

J Thorac Cardiovasc Surg. 2008 May;135(5):1110-9, 1119.e1-10. doi: 10.1016/j.jtcvs.2007.12.029.

PMID: 18455592 [PubMed – indexed for MEDLINE]

Related citations

Select item 19185140

 

7.

Effects of on- and off-pump coronary artery surgery on graft patency, survival, and health-related quality of life: long-term follow-up of 2 randomized controlled trials.

Angelini GD, Culliford L, Smith DK, Hamilton MC, Murphy GJ, Ascione R, Baumbach A, Reeves BC.

J Thorac Cardiovasc Surg. 2009 Feb;137(2):295-303. doi: 10.1016/j.jtcvs.2008.09.046.

PMID: 19185140 [PubMed – indexed for MEDLINE] Free PMC Article

Related citations

Select item 12086378

 

8.

Beating heart versus conventional reoperative coronary artery bypass surgery.

Mishra Y, Wasir H, Kohli V, Meharwal ZS, Bapna R, Mehta Y, Trehan N.

Indian Heart J. 2002 Mar-Apr;54(2):159-63.

PMID: 12086378 [PubMed – indexed for MEDLINE]

Related citations

Select item 22436550

 

9.

Evolution of Off-Pump Coronary Artery Bypass Grafting over 15 Years: A Single-Institution Experience of 14,030 Cases.

Mishra YK, Mishra M, Malhotra R, Meharwal ZS, Kohli V, Trehan N.

Innovations (Phila). 2005 Winter;1(2):88-91. doi: 10.1097/01.imi.0000189937.33748.19.

PMID: 22436550 [PubMed]

Related citations

Select item 16863772

 

10.

Propensity case-matched analysis of off-pump versus on-pump coronary artery bypass grafting in patients with atheromatous aorta.

Mishra M, Malhotra R, Karlekar A, Mishra Y, Trehan N.

Ann Thorac Surg. 2006 Aug;82(2):608-14.

PMID: 16863772 [PubMed – indexed for MEDLINE]

Related citations

Select item 18249555

 

11.

Late dialysis rate for coronary artery bypass grafting patients with moderate-to-severe renal impairment: comparison between off-pump and conventional method.

Yu HY, Li JY, Sun S, Hung KY, Wang JL, Chen YS, Wang SS, Lin FY.

Eur J Cardiothorac Surg. 2008 Mar;33(3):364-9. doi: 10.1016/j.ejcts.2007.12.027. Epub 2008 Feb 4.

PMID: 18249555 [PubMed – indexed for MEDLINE]

Related citations

Select item 11565659

 

12.

Off-pump bypass grafting is safe in patients with left main coronary disease.

Dewey TM, Magee MJ, Edgerton JR, Mathison M, Tennison D, Mack MJ.

Ann Thorac Surg. 2001 Sep;72(3):788-91; discussion 792.

PMID: 11565659 [PubMed – indexed for MEDLINE]

Related citations

Select item 15276508

 

13.

A prospective randomized study to evaluate stress response during beating-heart and conventional coronary revascularization.

Velissaris T, Tang AT, Murray M, Mehta RL, Wood PJ, Hett DA, Ohri SK.

Ann Thorac Surg. 2004 Aug;78(2):506-12; discussion 506-12.

PMID: 15276508 [PubMed – indexed for MEDLINE]

Related citations

Select item 12698142

 

14.

Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay: a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting.

Puskas JD, Williams WH, Duke PG, Staples JR, Glas KE, Marshall JJ, Leimbach M, Huber P, Garas S, Sammons BH, McCall SA, Petersen RJ, Bailey DE, Chu H, Mahoney EM, Weintraub WS, Guyton RA.

J Thorac Cardiovasc Surg. 2003 Apr;125(4):797-808.

PMID: 12698142 [PubMed – indexed for MEDLINE]

Related citations

Select item 16733171

 

15.

Relationship between atrial histopathology and atrial fibrillation after coronary bypass surgery.

Mariscalco G, Engström KG, Ferrarese S, Cozzi G, Bruno VD, Sessa F, Sala A.

J Thorac Cardiovasc Surg. 2006 Jun;131(6):1364-72.

PMID: 16733171 [PubMed – indexed for MEDLINE]

Related citations

Select item 14666033

 

16.

Combined use of off-pump techniques and a sutureless proximal aortic anastomotic device reduces cerebral microemboli generation during coronary artery bypass grafting.

Scarborough JE, White W, Derilus FE, Mathew JP, Newman MF, Landolfo KP; Neurological Outcome Research Group.

J Thorac Cardiovasc Surg. 2003 Nov;126(5):1561-7.

PMID: 14666033 [PubMed – indexed for MEDLINE]

Related citations

Select item 16305860

 

17.

Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis.

Chukwuemeka A, Weisel A, Maganti M, Nette AF, Wijeysundera DN, Beattie WS, Borger MA.

Ann Thorac Surg. 2005 Dec;80(6):2148-53.

PMID: 16305860 [PubMed – indexed for MEDLINE]

Related citations

Select item 21051050

 

18.

Is off-pump coronary artery bypass grafting superior to conventional bypass in octogenarians?

LaPar DJ, Bhamidipati CM, Reece TB, Cleveland JC, Kron IL, Ailawadi G.

J Thorac Cardiovasc Surg. 2011 Jan;141(1):81-90. doi: 10.1016/j.jtcvs.2010.09.012. Epub 2010 Nov 4.

PMID: 21051050 [PubMed – indexed for MEDLINE] Free PMC Article

Related citations

Select item 17258568

 

19.

Coronary artery bypass grafting with or without cardiopulmonary bypass in patients with preoperative non-dialysis dependent renal insufficiency: a randomized study.

Sajja LR, Mannam G, Chakravarthi RM, Sompalli S, Naidu SK, Somaraju B, Penumatsa RR.

J Thorac Cardiovasc Surg. 2007 Feb;133(2):378-88. Epub 2007 Jan 16.

PMID: 17258568 [PubMed – indexed for MEDLINE]

Related citations

Select item 14752428

 

20.

Coronary artery bypass grafting: are risk models developed from on-pump surgery valid for off-pump surgery?

Wu Y, Grunkemeier GL, Handy JR Jr.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):174-8.

PMID: 14752428 [PubMed – indexed for MEDLINE]

Related citations

Select item 21529848

 

21.

On-pump versus off-pump surgical revascularization in patients with acute coronary syndromes: analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial.

Ben-Gal Y, Stone GW, Smith CR, Williams MR, Weisz G, Stewart AS, Takayama H, Genereux P, Argenziano M.

J Thorac Cardiovasc Surg. 2011 Aug;142(2):e33-9. doi: 10.1016/j.jtcvs.2011.03.022. Epub 2011 Apr 29.

PMID: 21529848 [PubMed – indexed for MEDLINE]

Related citations

Select item 16482929

 

22.

Physiological comparison of off-pump and on-pump coronary artery bypass grafting in patients on chronic hemodialysis.

Manabe S, Arai H, Tanaka H, Tabuchi N, Sunamori M.

Jpn J Thorac Cardiovasc Surg. 2006 Jan;54(1):3-10.

PMID: 16482929 [PubMed – indexed for MEDLINE]

Related citations

Select item 16234622

 

23.

Coronary artery surgery: conventional coronary artery bypass grafting versus off-pump coronary artery bypass grafting.

Salzberg SP, Adams DH, Filsoufi F.

Curr Opin Cardiol. 2005 Nov;20(6):509-16. Review.

PMID: 16234622 [PubMed – indexed for MEDLINE]

Related citations

Select item 15063246

 

24.

On-pump versus off-pump coronary artery bypass grafting: impact on postoperative renal failure requiring renal replacement therapy.

Bucerius J, Gummert JF, Walther T, Schmitt DV, Doll N, Falk V, Mohr FW.

Ann Thorac Surg. 2004 Apr;77(4):1250-6.

PMID: 15063246 [PubMed – indexed for MEDLINE]

Related citations

Select item 19098331

 

25.

Outcomes of off-pump coronary artery bypass surgery: current best available evidence.

Raja SG, Berg GA.

Indian Heart J. 2007 Jan-Feb;59(1):15-27. Review.

PMID: 19098331 [PubMed – indexed for MEDLINE]

Related citations

Select item 23084105

 

26.

Off-pump coronary artery bypass grafting attenuates morbidity and mortality for patients with low and high body mass index.

Keeling WB, Kilgo PD, Puskas JD, Halkos ME, Lattouf OM, Guyton RA, Thourani VH.

J Thorac Cardiovasc Surg. 2012 Oct 16. doi:pii: S0022-5223(12)01147-6. 10.1016/j.jtcvs.2012.09.035. [Epub ahead of print]

PMID: 23084105 [PubMed – as supplied by publisher]

Related citations

Select item 16305858

 

27.

Perioperative patency of coronary artery bypass grafting is not influenced by off-pump technique.

Onorati F, Olivito S, Mastroroberto P, di Virgilio A, Esposito A, Perrotti A, Renzulli A.

Ann Thorac Surg. 2005 Dec;80(6):2132-40.

PMID: 16305858 [PubMed – indexed for MEDLINE]

Related citations

Select item 22002967

 

28.

Comparison of the effects of pulsatile cardiopulmonary bypass, non-pulsatile cardiopulmonary bypass and off-pump coronary artery bypass grafting on the inflammatory response and S-100beta protein.

Bayram H, Erer D, Iriz E, Zor MH, Gulbahar O, Ozdogan ME.

Perfusion. 2012 Jan;27(1):56-64. doi: 10.1177/0267659111424639. Epub 2011 Oct 14.

PMID: 22002967 [PubMed – indexed for MEDLINE]

Related citations

Select item 20447041

 

29.

Beating-heart coronary artery bypass grafting with miniaturized cardiopulmonary bypass results in a more complete revascularization when compared to off-pump grafting.

Reber D, Brouwer R, Buchwald D, Fritz M, Germing A, Lindstaedt M, Klak K, Laczkovics A.

Artif Organs. 2010 Mar;34(3):179-84. doi: 10.1111/j.1525-1594.2009.00836.x.

PMID: 20447041 [PubMed – indexed for MEDLINE]

Related citations

Select item 16740529

 

30.

Effect of off-pump coronary artery bypass surgery on clinical, angiographic, neurocognitive, and quality of life outcomes: randomised controlled trial.

Al-Ruzzeh S, George S, Bustami M, Wray J, Ilsley C, Athanasiou T, Amrani M.

BMJ. 2006 Jun 10;332(7554):1365. Epub 2006 Jun 1.

PMID: 16740529 [PubMed – indexed for MEDLINE] Free PMC Article

Related citations

Select item 12902131

 

31.

Off-pump long onlay bypass grafting using left internal mammary artery for diffusely diseased coronary artery.

Takanashi S, Fukui T, Hosoda Y, Shimizu Y.

Ann Thorac Surg. 2003 Aug;76(2):635-7.

PMID: 12902131 [PubMed – indexed for MEDLINE]

Related citations

Select item 12698147

 

32.

Endotoxemia in coronary artery bypass surgery: a comparison of the off-pump technique and conventional cardiopulmonary bypass.

Aydin NB, Gercekoglu H, Aksu B, Ozkul V, Sener T, Kiygil I, Turkoglu T, Cimen S, Babacan F, Demirtas M.

J Thorac Cardiovasc Surg. 2003 Apr;125(4):843-8.

PMID: 12698147 [PubMed – indexed for MEDLINE]

Related citations

Select item 11544625

 

33.

Progression to 100% off-pump coronary artery bypass with the Octopus 1 dual holder.

Roy A, Stanbridge RL, O’Regan D, Salerno G, Saldanha C, Griselli M, Cherian A.

Heart Surg Forum. 2001;4(2):174-8.

PMID: 11544625 [PubMed – indexed for MEDLINE]

Related citations

Select item 20083683

 

34.

No major differences in 30-day outcomes in high-risk patients randomized to off-pump versus on-pump coronary bypass surgery: the best bypass surgery trial.

Møller CH, Perko MJ, Lund JT, Andersen LW, Kelbaek H, Madsen JK, Winkel P, Gluud C, Steinbrüchel DA.

Circulation. 2010 Feb 2;121(4):498-504. doi: 10.1161/CIRCULATIONAHA.109.880443. Epub 2010 Jan 18.

PMID: 20083683 [PubMed – indexed for MEDLINE] Free Article

Related citations

Select item 22036259

 

35.

Off-pump coronary artery bypass grafting does not preserve renal function better than on-pump coronary artery bypass grafting: results of a case-matched study.

Elmistekawy E, Chan V, Bourke ME, Dupuis JY, Rubens FD, Mesana TG, Ruel M.

J Thorac Cardiovasc Surg. 2012 Jan;143(1):85-92. doi: 10.1016/j.jtcvs.2011.09.035. Epub 2011 Oct 27.

PMID: 22036259 [PubMed – indexed for MEDLINE]

Related citations

Select item 15173734

 

36.

Solid and gaseous cerebral microembolization during off-pump, on-pump, and open cardiac surgery procedures.

Abu-Omar Y, Balacumaraswami L, Pigott DW, Matthews PM, Taggart DP.

J Thorac Cardiovasc Surg. 2004 Jun;127(6):1759-65.

PMID: 15173734 [PubMed – indexed for MEDLINE]

Related citations

Select item 15172262

 

37.

Skeletonization of gastroepiploic artery graft in off-pump coronary artery bypass grafting: early clinical and angiographic assessment.

Kamiya H, Watanabe G, Takemura H, Tomita S, Nagamine H, Kanamori T.

Ann Thorac Surg. 2004 Jun;77(6):2046-50.

PMID: 15172262 [PubMed – indexed for MEDLINE]

Related citations

Select item 15561032

 

38.

Off-pump coronary artery bypass grafting in patients with renal dysfunction.

Tabata M, Takanashi S, Fukui T, Horai T, Uchimuro T, Kitabayashi K, Hosoda Y.

Ann Thorac Surg. 2004 Dec;78(6):2044-9.

PMID: 15561032 [PubMed – indexed for MEDLINE]

Related citations

Select item 16142517

 

39.

Diabetes in patients undergoing coronary artery bypass grafting. Impact on perioperative outcome.

Bucerius J, Gummert JF, Walther T, Doll N, Barten MJ, Falk V, Mohr FW.

Z Kardiol. 2005 Sep;94(9):575-82.

PMID: 16142517 [PubMed – indexed for MEDLINE]

Related citations

Select item 17053406

 

40.

Off-pump coronary artery bypass grafting through sternotomy: for whom?

Noora J, Puskas JD.

Curr Opin Cardiol. 2006 Nov;21(6):573-7. Review.

PMID: 17053406 [PubMed – indexed for MEDLINE]

Related citations

Select item 17384571

 

41.

A propensity score analysis on the effect of eliminating cardiopulmonary bypass for coronary artery bypass grafting.

Crescenzi G, Landoni G, Romano A, Boroli F, Giardina G, Bignami E, Fochi O, Aletti G, Rosica C, Zangrillo A.

Minerva Anestesiol. 2007 Mar;73(3):135-41.

PMID: 17384571 [PubMed – indexed for MEDLINE] Free Article

Related citations

Select item 17014446

 

42.

A single-blinded case controlled study on effects of cardiopulmonary circulation on hearing during coronary artery bypass grafting.

Donne AJ, Waterman P, Crawford L, Balaji HP, Nigam A.

Clin Otolaryngol. 2006 Oct;31(5):381-5.

PMID: 17014446 [PubMed – indexed for MEDLINE]

Related citations

Select item 20450302

 

43.

Reoperative off-pump coronary artery bypass grafting: current outcomes, concerns and controversies.

Raja SG, Amrani M.

Expert Rev Cardiovasc Ther. 2010 May;8(5):685-94. doi: 10.1586/erc.10.14. Review.

PMID: 20450302 [PubMed – indexed for MEDLINE]

Related citations

Select item 16399291

 

44.

Clinical outcomes of nonelective coronary revascularization with and without cardiopulmonary bypass.

Stamou SC, Hill PC, Haile E, Prince S, Mack MJ, Corso PJ.

J Thorac Cardiovasc Surg. 2006 Jan;131(1):28-33.

PMID: 16399291 [PubMed – indexed for MEDLINE]

Related citations

Select item 21281950

 

45.

Neurologic complications after off-pump coronary artery bypass grafting with and without aortic manipulation: meta-analysis of 11,398 cases from 8 studies.

Misfeld M, Brereton RJ, Sweetman EA, Doig GS.

J Thorac Cardiovasc Surg. 2011 Aug;142(2):e11-7. doi: 10.1016/j.jtcvs.2010.11.034. Epub 2011 Feb 1.

PMID: 21281950 [PubMed – indexed for MEDLINE]

Related citations

Select item 18805269

 

46.

Early and long-term outcomes in the elderly: comparison between off-pump and on-pump techniques in 1191 patients undergoing coronary artery bypass grafting.

Li Y, Zheng Z, Hu S.

J Thorac Cardiovasc Surg. 2008 Sep;136(3):657-64. doi: 10.1016/j.jtcvs.2007.12.069. Epub 2008 Jul 26.

PMID: 18805269 [PubMed – indexed for MEDLINE]

Related citations

Select item 16307999

 

47.

The role of tissue factor and P-selectin in the procoagulant response that occurs in the first month after on-pump and off-pump coronary artery bypass grafting.

Parolari A, Mussoni L, Frigerio M, Naliato M, Alamanni F, Polvani GL, Agrifoglio M, Veglia F, Tremoli E, Biglioli P, Camera M.

J Thorac Cardiovasc Surg. 2005 Dec;130(6):1561-6.

PMID: 16307999 [PubMed – indexed for MEDLINE]

Related citations

Select item 16153906

 

48.

Effects of off-pump versus on-pump coronary artery bypass grafting on function and viability of circulating endothelial progenitor cells.

Ruel M, Suuronen EJ, Song J, Kapila V, Gunning D, Waghray G, Rubens FD, Mesana TG.

J Thorac Cardiovasc Surg. 2005 Sep;130(3):633-9.

PMID: 16153906 [PubMed – indexed for MEDLINE]

Related citations

Select item 22523305

 

49.

On-pump versus off-pump coronary artery bypass surgery in elderly patients: results from the Danish on-pump versus off-pump randomization study.

Houlind K, Kjeldsen BJ, Madsen SN, Rasmussen BS, Holme SJ, Nielsen PH, Mortensen PE; DOORS Study Group.

Circulation. 2012 May 22;125(20):2431-9. doi: 10.1161/CIRCULATIONAHA.111.052571. Epub 2012 Apr 20.

PMID: 22523305 [PubMed – indexed for MEDLINE] Free Article

Related citations

Select item 17588377

 

50.

Off-pump coronary artery bypass grafting with skeletonized bilateral internal thoracic arteries in insulin-dependent diabetics.

Kai M, Hanyu M, Soga Y, Nomoto T, Nakano J, Matsuo T, Umehara E, Kawato M, Okabayashi H.

Ann Thorac Surg. 2007 Jul;84(1):32-6.

PMID: 17588377 [PubMed – indexed for MEDLINE]

Related citations

Select item 17703615

 

51.

[Coronary artery bypass grafting in patients with dialysis-dependent renal failure].

Mizumoto T, Adachi K, Hatanaka K, Sakamoto R, Seko H, Nakanishi R, Kinoshita T, Fujii H.

Kyobu Geka. 2007 Aug;60(9):785-9; discussion 790-3. Japanese.

PMID: 17703615 [PubMed – indexed for MEDLINE]

Related citations

Select item 19379976

 

52.

Surgical volume and outcomes of off-pump coronary artery bypass graft surgery: Does it matter?

Konety SH, Rosenthal GE, Vaughan-Sarrazin MS.

J Thorac Cardiovasc Surg. 2009 May;137(5):1116-23.e1. doi: 10.1016/j.jtcvs.2008.12.038. Epub 2009 Mar 25.

PMID: 19379976 [PubMed – indexed for MEDLINE]

Related citations

Select item 19782844

 

53.

Off-pump versus on-pump coronary artery bypass grafting.

Halkos ME, Puskas JD.

Surg Clin North Am. 2009 Aug;89(4):913-22, ix. doi: 10.1016/j.suc.2009.06.015. Review.

PMID: 19782844 [PubMed – indexed for MEDLINE]

Related citations

Select item 15224025

 

54.

Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques.

Casati V, Della Valle P, Benussi S, Franco A, Gerli C, Baili P, Alfieri O, D’Angelo A.

J Thorac Cardiovasc Surg. 2004 Jul;128(1):83-91.

PMID: 15224025 [PubMed – indexed for MEDLINE]

Related citations

Select item 10881825

 

55.

Stroke in octogenarians undergoing coronary artery surgery with and without cardiopulmonary bypass.

Ricci M, Karamanoukian HL, Abraham R, Von Fricken K, D’Ancona G, Choi S, Bergsland J, Salerno TA.

Ann Thorac Surg. 2000 May;69(5):1471-5.

PMID: 10881825 [PubMed – indexed for MEDLINE]

Related citations

Select item 23335652

 

56.

Haemostasis alterations in coronary artery bypass grafting: comparison between the off-pump technique and a closed coated cardiopulmonary bypass system.

Scrascia G, Rotunno C, Guida P, Conte M, Amorese L, Margari V, Schinosa Lde L, Paparella D.

Interact Cardiovasc Thorac Surg. 2013 May;16(5):636-42. doi: 10.1093/icvts/ivs525. Epub 2013 Jan 18.

PMID: 23335652 [PubMed – in process] Free Article

Related citations

Select item 22845813

 

57.

Myocardial revascularization for the elderly: current options, role of off-pump coronary artery bypass grafting and outcomes.

Raja SG.

Curr Cardiol Rev. 2012 Feb;8(1):26-36. Review.

PMID: 22845813 [PubMed – indexed for MEDLINE] Free PMC Article

Related citations

Select item 16286278

 

58.

Sternal wound complications in bilateral internal thoracic artery grafting: a comparison of the off-pump technique and conventional cardiopulmonary bypass.

Aydin NB, Sener T, Kehlibar IK, Turkoglu T, Karpuzoglu OE, Ozkul V, Gercekoglu H.

Heart Surg Forum. 2005;8(6):E456-61; discussion E461.

PMID: 16286278 [PubMed – indexed for MEDLINE]

Related citations

Select item 9768998

 

59.

Minimally invasive coronary artery bypass grafting: port-access approach versus off-pump techniques.

Reichenspurner H, Boehm DH, Welz A, Schmitz C, Wildhirt S, Schulze C, Meiser B, Schütz A, Reichart B.

Ann Thorac Surg. 1998 Sep;66(3):1036-40.

PMID: 9768998 [PubMed – indexed for MEDLINE]

Related citations

Select item 17888966

 

60.

Coronary artery bypass grafting with single cross-clamp results in fewer persistent neuropsychological deficits than multiple clamp or off-pump coronary artery bypass grafting.

Hammon JW, Stump DA, Butterworth JF, Moody DM, Rorie K, Deal DD, Kincaid EH, Oaks TE, Kon ND.

Ann Thorac Surg. 2007 Oct;84(4):1174-8; discussion 1178-9.

PMID: 17888966 [PubMed – indexed for MEDLINE]

Related citations

Select item 15236490

 

61.

Off-pump coronary artery bypass grafting versus on-pump coronary artery bypass grafting: which is better in patients with chronic obstructive pulmonary disease?

Zhu YB, Xu JP, Liu ZY, Yang DN, Li XD, Li HY.

J Zhejiang Univ Sci. 2004 Aug;5(8):1005-8.

PMID: 15236490 [PubMed – indexed for MEDLINE]

Related citations

Select item 9769005

 

62.

Off-pump multivessel coronary bypass via sternotomy is safe and effective.

Puskas JD, Wright CE, Ronson RS, Brown WM 3rd, Gott JP, Guyton RA.

Ann Thorac Surg. 1998 Sep;66(3):1068-72.

PMID: 9769005 [PubMed – indexed for MEDLINE]

Related citations

Select item 18329466

 

63.

Risk factors for wound infection after off-pump coronary artery bypass grafting: should bilateral internal thoracic arteries be harvested in patients with diabetes?

Nakano J, Okabayashi H, Hanyu M, Soga Y, Nomoto T, Arai Y, Matsuo T, Kai M, Kawatou M.

J Thorac Cardiovasc Surg. 2008 Mar;135(3):540-5. doi: 10.1016/j.jtcvs.2007.11.008.

PMID: 18329466 [PubMed – indexed for MEDLINE]

Related citations

Select item 18329463

 

64.

On-pump beating-heart coronary artery bypass grafting after acute myocardial infarction has lower mortality and morbidity.

Miyahara K, Matsuura A, Takemura H, Saito S, Sawaki S, Yoshioka T, Ito H.

J Thorac Cardiovasc Surg. 2008 Mar;135(3):521-6. doi: 10.1016/j.jtcvs.2007.10.006.

PMID: 18329463 [PubMed – indexed for MEDLINE]

Related citations

Select item 18329465

 

65.

The effects of on-pump and off-pump coronary artery bypass grafting on intraoperative graft flow in arterial and venous conduits defined by a flow/pressure ratio.

Balacumaraswami L, Abu-Omar Y, Selvanayagam J, Pigott D, Taggart DP.

J Thorac Cardiovasc Surg. 2008 Mar;135(3):533-9. doi: 10.1016/j.jtcvs.2007.10.027.

PMID: 18329465 [PubMed – indexed for MEDLINE]

Related citations

Select item 18381881

 

66.

Current status of off-pump coronary artery bypass surgery.

Raja SG, Dreyfus GD.

Asian Cardiovasc Thorac Ann. 2008 Apr;16(2):164-78. Review.

PMID: 18381881 [PubMed – indexed for MEDLINE]

Related citations

Select item 21421501

 

67.

[Circulating endothelial cell injury in on-pump and off-pump coronary-artery bypass grafting].

SONG TN, GAO BR, ZHAO QM.

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Mar;31(3):535-8. Chinese.

PMID: 21421501 [PubMed – indexed for MEDLINE] Free Article

Related citations

Select item 17599498

 

68.

Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery.

Ballotta A, Saleh HZ, El Baghdady HW, Gomaa M, Belloli F, Kandil H, Balbaa Y, Bettini F, Bossone E, Menicanti L, Frigiola A, Bellucci C, Mehta RH.

J Thorac Cardiovasc Surg. 2007 Jul;134(1):132-8.

PMID: 17599498 [PubMed – indexed for MEDLINE]

Related citations

Select item 14752424

 

69.

Equivalent midterm outcomes after off-pump and on-pump coronary surgery.

Sabik JF, Blackstone EH, Lytle BW, Houghtaling PL, Gillinov AM, Cosgrove DM.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):142-8.

PMID: 14752424 [PubMed – indexed for MEDLINE]

Related citations

Select item 23597624

 

70.

Outcomes of off-pump versus on-pump coronary artery bypass grafting: Impact of preoperative risk.

Polomsky M, He X, O’Brien SM, Puskas JD.

J Thorac Cardiovasc Surg. 2013 May;145(5):1193-8. doi: 10.1016/j.jtcvs.2013.02.002.

PMID: 23597624 [PubMed – indexed for MEDLINE]

Related citations

Select item 17670644

 

71.

Emergency conversion in off-pump coronary artery bypass grafting.

Tabata M, Takanashi S, Horai T, Fukui T, Hosoda Y.

Interact Cardiovasc Thorac Surg. 2006 Oct;5(5):555-9. Epub 2006 Jun 15.

PMID: 17670644 [PubMed] Free Article

Related citations

Select item 19379995

 

72.

A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery.

Sokal A, Zembala M, Radomski A, Kocher A, Pacholewicz J, Los J, Jedrzejczyk E, Zembala M, Radomski M.

J Thorac Cardiovasc Surg. 2009 May;137(5):1218-24. doi: 10.1016/j.jtcvs.2008.11.004. Epub 2009 Feb 23.

PMID: 19379995 [PubMed – indexed for MEDLINE]

Related citations

Select item 18815649

 

73.

Autologous bone marrow cell transplantation combined with off-pump coronary artery bypass grafting in patients with ischemic cardiomyopathy.

Yoo KJ, Kim HO, Kwak YL, Kang SM, Jang YS, Lim SH, Hwang KC, Cho SW, Yang YS, Li RK, Kim BS.

Can J Surg. 2008 Aug;51(4):269-75.

PMID: 18815649 [PubMed – indexed for MEDLINE] Free PMC Article

Related citations

Select item 20971248

 

74.

Left main coronary artery disease does not affect the outcome of off-pump coronary artery bypass grafting.

Suzuki T, Asai T, Matsubayashi K, Kambara A, Hiramatsu N, Kinoshita T, Nishimura O.

Ann Thorac Surg. 2010 Nov;90(5):1501-6. doi: 10.1016/j.athoracsur.2010.06.023.

PMID: 20971248 [PubMed – indexed for MEDLINE]

Related citations

Select item 11565657

 

75.

Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass.

Magee MJ, Dewey TM, Acuff T, Edgerton JR, Hebeler JF, Prince SL, Mack MJ.

Ann Thorac Surg. 2001 Sep;72(3):776-80; discussion 780-1.

PMID: 11565657 [PubMed – indexed for MEDLINE]

Related citations

Select item 11279409

 

76.

Reduced postoperative blood loss and transfusion requirement after beating-heart coronary operations: a prospective randomized study.

Ascione R, Williams S, Lloyd CT, Sundaramoorthi T, Pitsis AA, Angelini GD.

J Thorac Cardiovasc Surg. 2001 Apr;121(4):689-96.

PMID: 11279409 [PubMed – indexed for MEDLINE]

Related citations

Select item 12078783

 

77.

Evaluation of the effectiveness of off-pump coronary artery bypass grafting in high-risk patients: an observational study.

Chamberlain MH, Ascione R, Reeves BC, Angelini GD.

Ann Thorac Surg. 2002 Jun;73(6):1866-73.

PMID: 12078783 [PubMed – indexed for MEDLINE]

Related citations

Select item 11603449

 

78.

Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity.

Cleveland JC Jr, Shroyer AL, Chen AY, Peterson E, Grover FL.

Ann Thorac Surg. 2001 Oct;72(4):1282-8; discussion 1288-9.

PMID: 11603449 [PubMed – indexed for MEDLINE]

Related citations

Select item 22419321

 

79.

Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease.

Møller CH, Penninga L, Wetterslev J, Steinbrüchel DA, Gluud C.

Cochrane Database Syst Rev. 2012 Mar 14;3:CD007224. doi: 10.1002/14651858.CD007224.pub2. Review.

PMID: 22419321 [PubMed – indexed for MEDLINE]

Related citations

Select item 19559187

 

80.

In-hospital outcomes of off-pump multivessel total arterial and conventional coronary artery bypass grafting: single surgeon, single center experience.

Raja SG, Siddiqui H, Ilsley CD, Amrani M.

Ann Thorac Surg. 2009 Jul;88(1):47-52. doi: 10.1016/j.athoracsur.2009.04.013.

PMID: 19559187 [PubMed – indexed for MEDLINE]

Related citations

Select item 22197616

 

81.

Off-pump bilateral skeletonized internal thoracic artery grafting in elderly patients.

Kinoshita T, Asai T, Suzuki T, Kuroyanagi S, Hosoba S, Takashima N.

Ann Thorac Surg. 2012 Feb;93(2):531-6. doi: 10.1016/j.athoracsur.2011.09.077. Epub 2011 Dec 23.

PMID: 22197616 [PubMed – indexed for MEDLINE]

Related citations

Select item 12902081

 

82.

Is the use of cardiopulmonary bypass for multivessel coronary artery bypass surgery an independent predictor of operative mortality in patients with ischemic left ventricular dysfunction?

Al-Ruzzeh S, Athanasiou T, George S, Glenville BE, DeSouza AC, Pepper JR, Amrani M.

Ann Thorac Surg. 2003 Aug;76(2):444-51; discussion 451-2.

PMID: 12902081 [PubMed – indexed for MEDLINE]

Related citations

Select item 22154798

 

83.

On-pump versus off-pump coronary artery bypass surgery in high-risk patients: operative results of a prospective randomized trial (on-off study).

Lemma MG, Coscioni E, Tritto FP, Centofanti P, Fondacone C, Salica A, Rossi A, De Santo T, Di Benedetto G, Piazza L, Rinaldi M, Schinosa AL, De Paulis R, Contino M, Genoni M.

J Thorac Cardiovasc Surg. 2012 Mar;143(3):625-31. doi: 10.1016/j.jtcvs.2011.11.011. Epub 2011 Dec 10.

PMID: 22154798 [PubMed – indexed for MEDLINE]

Related citations

Select item 15854936

 

84.

Functional renal outcome in on-pump and off-pump coronary revascularization: a propensity-based analysis.

Weerasinghe A, Athanasiou T, Al-Ruzzeh S, Casula R, Tekkis PP, Amrani M, Punjabi P, Taylor K, Stanbridge R, Glenville B.

Ann Thorac Surg. 2005 May;79(5):1577-83.

PMID: 15854936 [PubMed – indexed for MEDLINE]

Related citations

Select item 16967324

 

85.

Does totally endoscopic access for off-pump cardiac surgery influence the incidence of postoperative atrial fibrillation in coronary artery bypass grafting? A preliminary report.

Scherer M, Sirat AS, Dogan S, Aybek T, Moritz A, Wimmer-Greinecker G.

Cardiovasc Eng. 2006 Sep;6(3):118-21.

PMID: 16967324 [PubMed – indexed for MEDLINE]

Related citations

Select item 18245699

 

86.

Off-pump coronary artery bypass grafting in left ventricular dysfunction.

Masoumi M, Saidi MR, Rostami F, Sepahi H, Roushani D.

Asian Cardiovasc Thorac Ann. 2008 Jan;16(1):16-20.

PMID: 18245699 [PubMed – indexed for MEDLINE]

Related citations

Select item 10536955

 

87.

Indication and patient selection in minimally invasive and òff-pump’ coronary artery bypass grafting.

Diegeler A, Matin M, Falk V, Binner C, Walther T, Autschbach R, Mohr FW.

Eur J Cardiothorac Surg. 1999 Sep;16 Suppl 1:S79-82.

PMID: 10536955 [PubMed – indexed for MEDLINE]

Related citations

Select item 15223396

 

88.

Trainees operating on high-risk patients without cardiopulmonary bypass: a high-risk strategy?

Ascione R, Reeves BC, Pano M, Angelini GD.

Ann Thorac Surg. 2004 Jul;78(1):26-33.

PMID: 15223396 [PubMed – indexed for MEDLINE]

Related citations

Select item 9262597

 

89.

Coronary artery bypass grafting “on pump”: role of three-day discharge.

Ott RA, Gutfinger DE, Miller MP, Selvan A, Codini MA, Alimadadian H, Tanner TM.

Ann Thorac Surg. 1997 Aug;64(2):478-81.

PMID: 9262597 [PubMed – indexed for MEDLINE]

Related citations

Select item 15784358

 

90.

Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?

Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T.

Eur J Cardiothorac Surg. 2005 Apr;27(4):606-10. Epub 2005 Jan 19.

PMID: 15784358 [PubMed – indexed for MEDLINE]

Related citations

Select item 15063245

 

91.

Coronary surgery in patients with peripheral vascular disease: effect of avoiding cardiopulmonary bypass.

Karthik S, Musleh G, Grayson AD, Keenan DJ, Pullan DM, Dihmis WC, Hasan R, Fabri BM.

Ann Thorac Surg. 2004 Apr;77(4):1245-9.

PMID: 15063245 [PubMed – indexed for MEDLINE]

Related citations

Select item 12538138

 

92.

Off-pump coronary artery bypass surgery–initial experience in Gdansk: a brief review.

Keita L, Anisimowicz L.

Heart Surg Forum. 2002;5(3):240-2.

PMID: 12538138 [PubMed – indexed for MEDLINE]

Related citations

Select item 12202877

 

93.

Improved outcomes in coronary artery bypass grafting with beating-heart techniques.

Mack M, Bachand D, Acuff T, Edgerton J, Prince S, Dewey T, Magee M.

J Thorac Cardiovasc Surg. 2002 Sep;124(3):598-607.

PMID: 12202877 [PubMed – indexed for MEDLINE]

Related citations

Select item 16399302

 

94.

Single crossclamp improves 6-month cognitive outcome in high-risk coronary bypass patients: the effect of reduced aortic manipulation.

Hammon JW, Stump DA, Butterworth JF, Moody DM, Rorie K, Deal DD, Kincaid EH, Oaks TE, Kon ND.

J Thorac Cardiovasc Surg. 2006 Jan;131(1):114-21. Epub 2005 Dec 9.

PMID: 16399302 [PubMed – indexed for MEDLINE]

Related citations

Select item 14635411

 

95.

[Right heart support during coronary artery bypass grafting without cardiopulmonary bypass].

Fernández AL, Tamayo E, Echevarría JR, Hernando MJ, Cubero T, Agudado MJ, López G.

Rev Med Univ Navarra. 2003 Apr-Jun;47(2):14-7. Spanish.

PMID: 14635411 [PubMed – indexed for MEDLINE]

Related citations

Select item 22698600

 

96.

Ten-year outcome analysis of off-pump sequential grafting: single surgeon, single center experience.

Raja SG, Salhiyyah K, Navaratnarajah M, Rafiq MU, Felderhof J, Walker CP, Ilsley CD, Amrani M.

Heart Surg Forum. 2012 Jun;15(3):E136-42. doi: 10.1532/HSF98.20111087.

PMID: 22698600 [PubMed – indexed for MEDLINE]

Related citations

Select item 23430415

 

97.

Monitoring brain oxygen saturation during awake off-pump coronary artery bypass.

Toda A, Watanabe G, Matsumoto I, Tomita S, Yamaguchi S, Ohtake H.

Asian Cardiovasc Thorac Ann. 2013 Feb;21(1):14-21. doi: 10.1177/0218492312444908.

PMID: 23430415 [PubMed – in process]

Related citations

Select item 9671898

 

98.

Coronary artery bypass grafting without cardiopulmonary bypass using the octopus method: results in the first one hundred patients.

Jansen EW, Borst C, Lahpor JR, Gründeman PF, Eefting FD, Nierich A, Robles de Medina EO, Bredée JJ.

J Thorac Cardiovasc Surg. 1998 Jul;116(1):60-7.

PMID: 9671898 [PubMed – indexed for MEDLINE]

Related citations

Select item 15282460

 

99.

Does off-pump total arterial grafting increase the incidence of intraoperative graft failure?

Balacumaraswami L, Abu-Omar Y, Anastasiadis K, Choudhary B, Pigott D, Yeong SK, Taggart DP.

J Thorac Cardiovasc Surg. 2004 Aug;128(2):238-44.

PMID: 15282460 [PubMed – indexed for MEDLINE]

Related citations

Select item 22436497

 

100.

Routine off-pump coronary artery bypass: reasons for on-pump conversion.

Hirose H, Amano A.

Innovations (Phila). 2005 Fall;1(1):28-31.

PMID: 22436497 [PubMed]

Related citations

Select item 18637191

 

101.

Rationale, design and methodology for a Prospective Randomized Study of graft patency in Off-pump and On-pump MultI-vessel coronary artery bypasS Surgery (PROMISS) using multidetector computed tomography.

Uva MS, Matias F, Cavaco S, Magalhães MP.

Trials. 2008 Jul 17;9:44. doi: 10.1186/1745-6215-9-44.

PMID: 18637191 [PubMed] Free PMC Article

Related citations

 

 

Read Full Post »

Can Resolvins Suppress Acute Lung Injury?

Reporter: Larry H Bernstein, MD, FCAP

Putting the brakes on acute lung injury: can resolvins suppress acute lung injury?

Cox RR Jr., Phillips O,and Kolliputi N

http://www.frontiersin.org Front.Physio. 2012;3:445.        http://dx.doi.org/10.3389/fphys.2012.00445
http://www.FrontPhysiol.com/putting_the_brakes_on_acute_lung_injury_can_resolvins_suppress_acute_lung_injury?/

The presence of resolvins, proresolving lipid mediators: their role in the resolution of ALI
Eickmeier et al.,
Mucosal Immunity 2012

conversion of DHA to RvD1 by

  • activation of RvD1 Receptor (ALX/FPR2) in pulmonary mucosa alleviates effects of inflammation in APALI

endogenous attenuation of inflammation in APALI
http://www.MucosalImmunity.com/Eikmeier/The_presence_of_resolvins:_their_role_in_the_resolution_of_ALI

 Putting the brakes on acute lung injury: can resolvins suppress acute lung injury?
Ruan R. Cox Jr., Oluwakemi Phillips and Narasaiah Kolliputi*
Front Physiol. 2012;3:445.   doi: 10.3389/fphys.2012.00445. Epub 2012 Nov 29.       http://dx.doi.org/10.3389/fphys.2012.00445
http://fphys.com/Putting the brakes on acute lung injury: can resolvins suppress acute lung injury?

A commentary on

Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury

by Eickmeier, O., Seki, H., Haworth, O., Hilberath, J. N., Gao, F., Uddin, M., et al. (2012). Mucosal Immunol. doi: 10.1038/mi.2012.66

Acute lung injury (ALI), a syndrome of respiratory failure, is a major clinical problem in the United States. With a high incidence rate, affecting nearly 200,000 annually and a significant morbidity and mortality rate, ALI represents a significant source of health care expenditure with a cost of 3.5–6 billion dollars annually (Treggiari et al., 2004; Rubenfeld et al., 2005; Raghavendran et al., 2011). Pneumocytes, unique cells in the alveolar epithelium, are responsible for

  • facilitating gas exchange,
  • regulating fluid transport, and
  • secreting surfactant to reduce alveolar surface tension.

When the alveolar barrier is disrupted, proteinaceous exudates and extracellular components of necrotic pneumocytes activate resident alveolar macrophages causing massive cytokine release (Ware and Matthay, 2000).  The inflammatory response, if left uncontrolled, can lead to further deterioration of the lung epithelium and the development of a fibroproliferative environment (Raghavendran et al., 2011).

In the July 2012 issue of Mucosal Immunity, Eickmeier et al., discuss the presence of

  1. resolvins,
  2. proresolving lipid mediators, and
  3. present exciting findings on their role in the natural resolution of ALI (Eickmeier et al., 2012).

Resolution phase interaction products (resolvins) are omega-3 polyunsaturated fatty acid derivatives of potent anti-inflammatory precursors, eicosapentaenoic acid (EPA), and docasahexaenoic acid (DHA) (Serhan et al., 2002). “E-series” and “D-series” resolvins are derived from EPA and DHA, respectively. The airway mucosa has been shown to be rich in DHA (Freedman et al., 2004), however, the conversion of DHA to D-series resolvins has not been shown. Resolvin D1 (RvD1), a derivative of DHA, has been found in murine resolving inflammatory peritoneal exudates (Serhan et al., 2002). To investigate the potential role that RvD1 may play in the resolution of ALI, Eickmeier et al. used a murine aspiration pneumonitis acute lung injury (APALI) model induced by hydrochloric acid (HCl) administration into the left lung. Picogram quantities of RvD1 were found using metabolipidomics analysis following HCl instillation. Immunohistochemical analysis showed enhanced expression of RvD1 receptor (ALX/FPR2) as early as 2 h post-APALI. This suggested that there was a conversion of DHA to RvD1 following lung injury. Activation of ALX/FPR2 dampens the inflammatory responses through blockage of proinflammatory MAP kinase and NF-κB signaling (Chiang et al., 2006).  Eickmeier et al. demonstrated that the conversion of DHA in pulmonary mucosa alleviates the effects of inflammation in APALI. AT-RvD1 showed therapeutic effects, and bronchio-alveolar lavage fluid (BALF) collected from AT-RvD1 treated mice contained decreased leukocytes and proinflammatory cytokines in comparison to control. AT-RvD1 treated mice demonstrated decreased lung resistance and improved lung mechanics in comparison to controls. The authors showed that AT-RvD1 restored barrier integrity in APALI mice in comparison to control. The anti-inflammatory effects of ALX/FPR2 activation were shown to be a result of

  • reduced activation and nuclear translocation of the transcription factor NF-κB.

Eickmeier et al., demonstrated that mice treated with AT-RvD1 demonstrated reduced

  • NF-κB phosphorylation, which is necessary for the activation,
  • translocation and DNA binding functions of this proinflammatory molecule.

The work of Eickmeier et al. revealed that RvD1 is a central mediator in the endogenous attenuation of inflammation seen in APALI. In most cases of ALI, the injury is indeed self-limiting and resolves on its own (Dos Santos and Slutsky, 2006). This work gives insight to the mechanism involved in the lung injury resolution process. A recent clinical study demonstrates that,
ALI progression is associated with

  • increased ventilator time and
  • longer intensive care unit (ICU) stays.

These patients show an enhanced proinflammatory cytokine profile which was also correlated with increased morbidity (Dolinay et al., 2012). Previous reports have also demonstrated that ALI/ARDS patients represent 34% of yearly costs for all ICU trauma patients (Treggiari et al., 2004). In the case that the ALI does not resolve, the patient is at risk for developing acute respiratory distress syndrome in as little as 3 days (Marshall et al., 1998). Finding endogenous mediators that may control the ungoverned inflammation seen in ALI is a pivotal step to finding a treatment for this disease that entails more than just supportive care (Marshall et al., 1998). The work of Eickmeier et al. has paved the way for the exploration of the beneficial effects of resolvins in the incidences of other sterile injuries, such as atherosclerosis, gout, Alzheimer’s disease, and diabetes.

Br J Pharmacol. 2008 March; 153(S1): S200–S215.
Published online 2007 October 29. doi:  10.1038/sj.bjp.0707489
PMCID: PMC2268040

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

C N Serhan1,2,* and N Chiang1
This article has been cited by other articles in PMC.

Abstract

Complete resolution of an acute inflammatory response and its return to homeostasis are essential for healthy tissues. We here consider work to characterize cellular and molecular mechanisms that govern the resolution of self-limited inflammation. Systematic temporal analyses of evolving inflammatory exudates using

  1. mediator lipidomics-informatics,
  2. proteomics, and
  3. cellular trafficking with murine resolving exudates demonstrate
    • novel endogenous pathways of local-acting mediators that share both anti-inflammatory and pro-resolving properties.

In murine systems, resolving-exudate leukocytes switch their phenotype to actively generate new families of mediators from major omega-3 fatty acids EPA and DHA termed resolvins and protectins. Recent advances on their biosynthesis and actions are reviewed with a focus on the E-series resolvins (RvE1, RvE2), D series resolvins (RvD1, RvD2) and the protectins including neuroprotectin D1/protectin D1 (NPD1/PD1) as well as their aspirin-triggered epimeric forms.  These endogenous agonists of resolution pathways constitute a novel genus of chemical mediators that possess

  • pro-resolving,
  • anti-inflammatory, and
  • antifibrotic as well as
  • host-directed antimicrobial actions.
    These may be useful in the design of new therapeutics and treatments for diseases with the underlying trait of uncontrolled inflammation and redox organ stress.
Keywords: leukocytes, eicosanoids, resolvins, acute inflammation, ω-3 fatty acids, protectins

Introduction

Acute inflammation has several outcomes that include

  • progression to chronic inflammation,
  • scarring and fibrosis or
  • complete resolution (Cotran et al., 1999).

With the isolation of endogenous anti-inflammatory and pro-resolving mediators and their characterization, it became clear that resolution is an active process involving biochemical circuits that

The resolution phase has emerged as a new terrain for drug design and resolution-directed therapeutics (Gilroy et al., 2004Lawrence et al., 2005). A pro-resolving small molecule can, in addition to serving as

  • an agonist of anti-inflammation, also
  • promote the uptake and clearance of apoptotic neutrophils (polymorphonuclear leukocyte, PMN)

A recent consensus report from investigators at the forefront of this emerging area has addressed these definitions to help delineate this new terrain (Serhan et al., 2007). Some agents such as the widely used COX-2 inhibitors proved to be resolution toxic (Gilroy et al., 1999Bannenberg et al., 2005Serhan et al., 2007), whereas others can possess pro-resolving actions, such as

Interest in natural resolving mechanisms has been heightened in recent years (Henson, 2005Luster et al., 2005Serhan and Savill, 2005) because inflammation (characterized by the cardinal symptoms dolor, calor, rubor and loss of function) is now recognized as a central feature in the pathogenesis of many prevalent diseases in modern Western civilization, such as

  1. stroke,
  2. Alzheimer’s and
  3. Parkinson’s diseases (Majno and Joris, 1996;Nathan, 2002Erlinger et al., 2004Hansson et al., 2006).

Resolution of inflammation is required for the return from inflammatory disease to health, that is, catabasis (Bannenberg et al., 2005). New evidence from this laboratory and others indicates that the catabasis from inflammation to the ‘normal’ noninflamed state is not merely passive termination of inflammation but rather an actively regulated program of resolution (Serhan et al., 2007). This event is accompanied by lipid mediator class switching from pro-inflammatory prostaglandins (PGs) and leukotrienes (LT) to the biosynthesis of anti-inflammatory mediators, such as lipoxins (LXs) (Levy et al., 2001), as well as the appearance of new families of pro-resolving mediators biosynthesized in exudates from ω-3 polyunsaturated fatty acid (PUFA) precursors (Serhan et al., 20002002Hong et al., 2003) (Figure 1a).   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268040/bin/0707489f1.gif

The essential roles of omega-3 PUFAs in preventing disease in rodents were established in 1929 (Burr and Burr, 1929). In humans, the beneficial actions of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the major omega-3 PUFA, remains a topic of interest because structure–activity relationships remained to be established.  One theory suggests that the omega-3 PUFA compete with the storage of arachidonic acid (AA),

  • replacing it and blocking the production of pro-inflammatory eicosanoids (Lands, 1987).

Along with the pro-inflammatory PGs and LT, the n−6 essential fatty acid AA is precursor to LX and aspirin-triggered LX, which possess potent anti-inflammatory and pro-resolving actions. Therefore, the popular view of essential n−6 and n−3 PUFA actions in inflammation and homeostasis was incomplete.   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268040/table/tbl1/?report=thumb

The evidence available to date  indicates that

The term resolvins (resolution-phase interaction products) was first introduced to signify that the new structures were endogenous mediators possessing potent anti-inflammatory and immunomodulatory actions demonstrated in the nanogram dose range in vivo(Serhan et al., 2002). These include

  • reducing neutrophil traffic and pro-inflammatory cytokines, as well as
  • lowering the magnitude of the inflammatory response in vivo (Serhan et al., 20002002).

The terms protectin and neuroprotectin (when generated in neural tissues) (Serhan et al., 2006a) were introduced given the anti-inflammatory (Hong et al., 2003) as well as the protective actions of the
DHA-derived mediator NPD1/PD1 in neural systems (Mukherjee et al., 2004),

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268040/bin/0707489f2.gif

RvE1 possesses an interesting and novel distinct structure consisting of

  • a conjugated diene plus
  • conjugated diene chromophore present within the same molecule.

Both biogenic (Serhan et al., 2000) and total organic syntheses were achieved and its complete stereochemical assignment was established along with that of several related natural isomers (Arita et al., 2005a). RvE1 proved to be 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoicacid.

Human recombinant 5-LOX generates resolvin E2 (RvE2) from a common precursor of E-series resolvins, namely 18-HEPE. RvE2, which is 5S,18-dihydroxyeicosapentaenoic acid, stopped zymosan-induced PMN infiltration, displaying potent anti-inflammatory properties in murine peritonitis (Tjonahen et al., 2006). In addition, RvE1 and RvE2, when given together, displayed additive action in controlling PMN infiltration. These results demonstrate that RvE2, together with RvE1, may contribute to the beneficial actions of ω-3 fatty acids in human diseases. Moreover, they indicate that the 5-LOX, in human leukocytes, is a pivotal enzyme that is temporally and spatially regulated in vivo to produce either pro- or anti-inflammatory local chemical mediators.

Resolvins of the E-series comprise several molecules. Among them, RvE1 was the first isolated and studied in depth. RvE1 displayed potent stereoselective actions in vivo and with isolated cells.
At nanomolar levels in vitro, RvE1 dramatically reduced

  1. human PMN transendothelial migration,
  2. dendritic cell (DC) migration and
  3. interleukin (IL)-12 production
    (Serhan et al., 2002Arita et al., 2005a).

These new findings provide evidence for

  • endogenous mechanism(s) that may account for some of the widely touted beneficial actions noted with dietary supplementation with ω-3 PUFA (EPA and DHA),
  • thereby providing new approaches for the treatment of gastrointestinal mucosal and oral inflammation.

The new families of EPA- and DHA-derived chemical mediators, namely the resolvins and protectins, qualify as ‘resolution agonists’ along with the n−6 derived agonists of resolution, the LX, in this new arena of immunomodulation and tissue protection. These are conserved structures in evolution, because rainbow trout biosynthesize resolvins and protectins, which are present in their neural and hematopoietic tissues (Hong et al., 2005). Their functional roles in fish and lower phyla remain to be established, but are likely to involve

  1. cell trafficking,
  2. motility and
  3. protection.

Additionally, they now open new avenues to design ‘resolution-targeted’-based therapies where aberrant uncontrolled inflammation and/or impaired resolution are components of the disease pathophysiology.

Lipoxin A4 Regulates Natural Killer Cell and Type 2 Innate Lymphoid Cell Activation in Asthma
C Barnig, M Cernadas, S Dutile,…BR Levy.
Sci Transl Med 27 Feb 2013: 5(174) 174ra26   http://dx.doi.org/10.1126/scitranslmed.3004812   http://www.scitranslmed.com//LipoxinA4_Regulates_Natural_Killer_Cell_and_Type2_Innate_Lymphoid_Cell_Activation_in_Asthma/


Asthma is a prevalent disease of chronic inflammation in which endogenous counterregulatory signaling pathways are dysregulated. Recent evidence suggests that innate lymphoid cells (ILCs), including natural killer (NK) cells and type 2 ILCs (ILC2s), can participate in the regulation of allergic airway responses, in particular airway mucosal inflammation.
Both NK cells and ILC2s expressed

Lipoxin A4, a natural pro-resolving ligand for ALX/FPR2 receptors, significantly

Together, these findings indicate that ILCs are targets for lipoxin A4 to decrease airway inflammation and mediate the catabasis of eosinophilic inflammation

Neutrophil granulocyte migrates from the blood...

Neutrophil granulocyte migrates from the blood vessel to the matrix, sensing proteolytic enzymes, in order to determine intercellular connections (to the improvement of its mobility) and envelop bacteria through Phagocytosis. (Photo credit: Wikipedia)

Read Full Post »